معرفی
Helen E Heslop, MD, DSc (Hon), is a Professor in the Departments of Medicine and Pediatrics, Section of Hematology-Oncology at Baylor College of Medicine. She serves as Director of the Center for Cell and Gene Therapy and holds the Dan L Duncan Chair at the Dan L Duncan Comprehensive Cancer Center. Her expertise lies in translational research focusing on adoptive immunotherapy using gene-modified T cells to treat hematologic malignancies and improve outcomes in stem cell transplantation. Dr. Heslop has pioneered therapies for Epstein-Barr virus (EBV)-related lymphoproliferative diseases and advanced cancers, with a focus on CAR-T cell engineering and antiviral immunity.
Educated at the University of Otago (New Zealand), she completed advanced training in the UK and New Zealand. Her honors include election to the National Academy of Medicine (2021) and leadership roles in major societies like the American Society of Gene and Cell Therapy. Her research integrates clinical trials, viral immunology, and novel antigen targeting to advance cancer therapies. Ongoing work includes studies on CAR-T cell efficacy, solid tumor immunotherapy, and mitigating post-transplant complications.
Her scientific contributions span over 300 publications, with recent focus on GD2-directed CAR-T for neuroblastoma, viral-specific T-cell therapies, and optimizing CAR-T safety via cytokine engineering. She leads multicenter trials evaluating novel cell therapies and their long-term impacts, emphasizing translational research from lab to clinic.
